These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 16323137)

  • 1. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Huang JF; Hsieh MY; Wang LY; Yu ML
    J Infect Dis; 2006 Jan; 193(1):98-101. PubMed ID: 16323137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
    Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
    Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C.
    Dai CY; Chuang WL; Lee LP; Chen SC; Hou NJ; Lin ZY; Hsieh MY; Hsieh MY; Wang LY; Chang WY; Yu ML
    J Viral Hepat; 2006 Nov; 13(11):770-4. PubMed ID: 17052277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2005 Aug; 67(2):93-7. PubMed ID: 16051377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
    Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
    Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-alpha therapy.
    Tena-Tomás C; Pedroso ML; de Messias-Reason IJ; Kremsner PG; Kun JF
    Eur Cytokine Netw; 2007 Sep; 18(3):136-41. PubMed ID: 17823081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
    Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
    J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.
    Mueller T; Mas-Marques A; Sarrazin C; Wiese M; Halangk J; Witt H; Ahlenstiel G; Spengler U; Goebel U; Wiedenmann B; Schreier E; Berg T
    J Hepatol; 2004 Oct; 41(4):652-8. PubMed ID: 15464247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism.
    Schiemann U; Glas J; Török P; Simperl C; Martin K; König A; Schmidt F; Schaefer M; Folwaczny C
    Digestion; 2003; 68(1):1-4. PubMed ID: 12949432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha.
    Yu ML; Dai CY; Chiu CC; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chen CJ; Chuang WL; Chang WY
    Antiviral Res; 2003 Jun; 59(1):35-40. PubMed ID: 12834858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic differences in polymorphisms of tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in patients with chronic hepatitis C virus infection.
    Zein NN; Germer JJ; El-Zayadi AR; Vidigal PG
    Am J Trop Med Hyg; 2004 Apr; 70(4):434-7. PubMed ID: 15100460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interferon therapy on fatty acid saturation index in hepatitis C virus infection.
    Abdel Aziz MT; Abdel-Ghaffar Y; Fouad HH; Abdel Aziz DM; el-Magd AA
    East Mediterr Health J; 2001; 7(4-5):779-86. PubMed ID: 15332779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C.
    Aguilar-Reina J; Ruiz-Ferrer M; Pizarro MA; Antiñolo G
    J Viral Hepat; 2005 Nov; 12(6):568-73. PubMed ID: 16255757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.